# Arformoterol/Budesonide for COVID-19

> **NCT05055414** · PHASE2 · UNKNOWN · sponsor: **Korea United Pharm. Inc.** · enrollment: 140 (estimated)

## Conditions studied

- Coronavirus Infection

## Interventions

- **DRUG:** UI030

## Key facts

- **NCT ID:** NCT05055414
- **Lead sponsor:** Korea United Pharm. Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-01
- **Primary completion:** 2022-10-01
- **Final completion:** 2022-11-01
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2021-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05055414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05055414, "Arformoterol/Budesonide for COVID-19". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05055414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*